Resistance Mechanisms to Combined Trametinib and 4-aminoquinolones in the Inhibition of Pancreatic Cancer

曲美替尼联合 4-氨基喹诺酮类药物抑制胰腺癌的耐药机制

基本信息

  • 批准号:
    10437778
  • 负责人:
  • 金额:
    $ 27.29万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-01 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

Abstract: The RAS-regulated RAFMEKERK MAP kinase pathway is a central pathway for pancreatic cancer initiation as 95% of pancreatic adenocarcinomas express mutationally activated KRAS. To date, however, targeting downstream components of KRAS signaling in clinical trials have not shown efficacy. Autophagy has also been shown to be important for pancreatic cancer tumorigenesis, however, clinical trials have been disappointing with chloroquine/hydroxychloroquine (4-aminoquinolones) treatment in conjunction with standard chemotherapy. We have recently demonstrated that combined inhibition of both MEK 1/2 and autophagy results in in vitro cytotoxicity and dramatic in vivo tumor regression in a recent publication in Nature Medicine, which was extended to a single pancreatic cancer patient with no therapeutic options left who demonstrated a dramatic tumor burden reduction of ~50% after 4 months of therapy of combined trametinib and hydroxychloroquine. Two Phase I/II clinical trials have resulted from the work and are either accruing or soon to open. The long-term goals of my research as a physician-scientist is to contribute a deeper mechanistic understating of KRAS signaling in pancreatic cancer and design successful clinical strategies to improve outcomes for one of the most treatment resistant human malignancies. The short-term goals of this K08 application are to understand the resistance mechanisms to trametinib and hydroxychloroquine to determine predictive biomarkers and how to overcome resistance. My immediate career goals over the next 5 years include updating and broadening my knowledge of cancer biology, becoming proficient in grant writing, accomplishing the AIMS outlined in this proposal, publishing the results, assisting in designing and executing clinical trials resulting from the work, securing grants, continued expansion of laboratory personnel, generating R01 applications, and establishing excellence in my clinical practice. My long term career goals include building an enterprise of investigations into the discovery of therapeutic targets for treating gastrointestinal malignancies, furthering the field of understanding of the role for autophagy in malignancy, and training the next generation of physicians and scientists. My mentors include Martin McMahon, PhD, G. Weldon Gilcrease III, MD and Ignacio Garrido-Laguna, MD, PhD. Dr. McMahon provides me with laboratory space and expertise in RAFMEKERK MAP kinase signaling, pre-clinical modeling and pancreatic cancer cell biology. Dr. Gilcrease is a GI Oncologist provides guidance with clinical responsibilities. Dr. Garrido-Laguna is a GI Oncologist with expertise in pancreatic cancer and clinical trials, who will advise in designing and executing anticipated clinical trials that will result from this body of work. In addition to these excellent mentors in basic science and clinical pursuits I will also have the support of the Preclinical Research Resource Core and collaboration with Courtney Scaife, MD and Jill Shea, PhD who will assist with preclinical model PDX establishment and testing. In summary I will have an excellent environment to further my career with guidance and support for basic science, translational science, and clinical investigation.
摘要: RAS调控的RAFMEKERK MAP激酶通路是胰腺癌的中枢通路。 95% 的胰腺腺癌表达突变激活的 KRAS,从而引发癌症。然而,迄今为止, 临床试验中针对 KRAS 信号下游成分的药物尚未显示出疗效。自噬有 也被证明对胰腺癌肿瘤发生很重要,然而,临床试验已证实 氯喹/羟氯喹(4-氨基喹诺酮类)联合标准治疗令人失望 化疗。我们最近证明,MEK 1/2 和自噬的联合抑制会产生 在《自然医学》最近发表的一篇文章中,研究了体外细胞毒性和体内肿瘤显着消退,其中 扩展到一名没有治疗选择的胰腺癌患者,该患者表现出戏剧性的效果 曲美替尼和羟氯喹联合治疗 4 个月后,肿瘤负荷减少约 50%。二 I/II 期临床试验已经取得成果,并且正在积累或即将开始。长期目标 作为一名医师兼科学家,我的研究目标是对 KRAS 信号转导机制有更深入的理解 胰腺癌并设计成功的临床策略以改善最有效治疗方法之一的结果 抵抗人类恶性肿瘤。该 K08 应用程序的短期目标是了解电阻 曲美替尼和羟氯喹确定预测生物标志物的机制以及如何克服 反抗。我未来 5 年的近期职业目标包括更新和拓宽我的知识 癌症生物学,精通资助写作,实现本提案中概述的目标,出版 结果,协助设计和执行工作产生的临床试验,获得资助,继续 扩大实验室人员,生成 R01 应用程序,并在我的临床领域建立卓越的表现 实践。我的长期职业目标包括建立一家研究发现的企业 治疗胃肠道恶性肿瘤的治疗靶点,进一步加深了对其作用的理解 恶性肿瘤中的自噬,并培训下一代医生和科学家。我的导师包括 Martin McMahon 博士、G. Weldon Gilcrease III 医学博士和 Ignacio Garrido-Laguna 医学博士、博士。麦克马洪博士 为我提供了 RAFMEKERK MAP 激酶信号传导、临床前的实验室空间和专业知识 建模和胰腺癌细胞生物学。 Gilcrease 博士是一位胃肠道肿瘤学家,提供临床指导 责任。 Garrido-Laguna 博士是一位胃肠道肿瘤学家,在胰腺癌和临床试验方面拥有专业知识, 将就设计和执行这项工作所产生的预期临床试验提供建议。此外 感谢这些基础科学和临床研究方面的优秀导师,我还将得到临床前研究团队的支持 研究资源核心以及与 Courtney Scaife 医学博士和 Jill Shea 博士的合作,他们将协助 临床前PDX模型的建立和测试。总而言之,我将有一个良好的环境来进一步发展我的事业。 为基础科学、转化科学和临床研究提供指导和支持的职业生涯。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Conan Kinsey其他文献

Conan Kinsey的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Conan Kinsey', 18)}}的其他基金

Resistance Mechanisms to Combined Trametinib and 4-aminoquinolones in the Inhibition of Pancreatic Cancer
曲美替尼联合 4-氨基喹诺酮类药物抑制胰腺癌的耐药机制
  • 批准号:
    10055658
  • 财政年份:
    2020
  • 资助金额:
    $ 27.29万
  • 项目类别:
Resistance Mechanisms to Combined Trametinib and 4-aminoquinolones in the Inhibition of Pancreatic Cancer
曲美替尼联合 4-氨基喹诺酮类药物抑制胰腺癌的耐药机制
  • 批准号:
    10197024
  • 财政年份:
    2020
  • 资助金额:
    $ 27.29万
  • 项目类别:
Resistance Mechanisms to Combined Trametinib and 4-aminoquinolones in the Inhibition of Pancreatic Cancer
曲美替尼联合 4-氨基喹诺酮类药物抑制胰腺癌的耐药机制
  • 批准号:
    10656403
  • 财政年份:
    2020
  • 资助金额:
    $ 27.29万
  • 项目类别:

相似国自然基金

基于Teach-back药学科普模式的慢阻肺患者吸入用药依从性及疗效研究
  • 批准号:
    2024KP61
  • 批准年份:
    2024
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
基于Quench-Back保护的超导螺线管磁体失超过程数值模拟研究
  • 批准号:
    51307073
  • 批准年份:
    2013
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

CAREER: From Dynamic Algorithms to Fast Optimization and Back
职业:从动态算法到快速优化并返回
  • 批准号:
    2338816
  • 财政年份:
    2024
  • 资助金额:
    $ 27.29万
  • 项目类别:
    Continuing Grant
One-step reconstruction of plastic waste back to its constituent monomers (ONESTEP)
将塑料废物一步重建回其组成单体(ONESTEP)
  • 批准号:
    EP/Y003934/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.29万
  • 项目类别:
    Research Grant
On the origin of very massive back holes
关于巨大背洞的起源
  • 批准号:
    DP240101786
  • 财政年份:
    2024
  • 资助金额:
    $ 27.29万
  • 项目类别:
    Discovery Projects
Back to our roots: Re-activating Indigenous biocultural conservation
回到我们的根源:重新激活本土生物文化保护
  • 批准号:
    FT230100595
  • 财政年份:
    2024
  • 资助金额:
    $ 27.29万
  • 项目类别:
    ARC Future Fellowships
Collaborative Research: FuSe: Indium selenides based back end of line neuromorphic accelerators
合作研究:FuSe:基于硒化铟的后端神经形态加速器
  • 批准号:
    2328741
  • 财政年份:
    2023
  • 资助金额:
    $ 27.29万
  • 项目类别:
    Continuing Grant
Collaborative Research: NSFGEO-NERC: MEZCAL: Methods for Extending the horiZontal Coverage of the Amoc Latitudinally and back in time (MEZCAL)
合作研究:NSFGEO-NERC:MEZCAL:扩展 Amoc 纬度和时间回水平覆盖范围的方法 (MEZCAL)
  • 批准号:
    2409764
  • 财政年份:
    2023
  • 资助金额:
    $ 27.29万
  • 项目类别:
    Standard Grant
Relationships Between Pain-Related Psychological Factors, Gait Quality, and Attention in Chronic Low Back Pain
慢性腰痛中疼痛相关心理因素、步态质量和注意力之间的关系
  • 批准号:
    10679189
  • 财政年份:
    2023
  • 资助金额:
    $ 27.29万
  • 项目类别:
The Role of VEGF in the Development of Low Back Pain Following IVD Injury
VEGF 在 IVD 损伤后腰痛发展中的作用
  • 批准号:
    10668079
  • 财政年份:
    2023
  • 资助金额:
    $ 27.29万
  • 项目类别:
Psilocybin and Affective Function in Chronic Lower Back Pain and Depression
裸盖菇素与慢性腰痛和抑郁症的情感功能
  • 批准号:
    10626449
  • 财政年份:
    2023
  • 资助金额:
    $ 27.29万
  • 项目类别:
Brain Mechanisms of Chronic Low-Back Pain: Specificity and Effects of Aging and Sex
慢性腰痛的脑机制:衰老和性别的特异性和影响
  • 批准号:
    10657958
  • 财政年份:
    2023
  • 资助金额:
    $ 27.29万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了